A Study of HG146 Capsule in Chinese Subjects with Relapsed and Refractory Multiple Myeloma

This study is designed to evaluate the tolerability and safety of HG146 capsule in patients with multiple myeloma.

Sex

All

Minimum age

18 Years

Maximum age

75 Years

Inclusion Criteria:

* Diagnosis of multiple myeloma requiring systemic therapy (International Myeloma Working Group \[IMWG\]) and 2 cycles of treatment including proteasome inhibitors and/or immunomodulators.
* Serum M protein≥ 10.0g / L, or urine M protein ≥ 200mg / 24h.
* Not suitable for autologous bone marrow transplantation or refuse autologous bone marrow transplantation or relapse after autologous bone marrow transplantation.
* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 or 2.
* Expected survival of ≥3 months.
* Hemoglobin ≥ 80 g/L, Platelet≥75×10\^9/L, Absolute Neutrophil Count≧1.0×109/L (1000 cells/mm3), Prothrombin time(PT) and activated partial thromboplastin time ≤ 2 x Upper Limit of Normal (ULN).
* Bilirubin in serum\<1.5\*ULN (2.0mg/dL/20mg/L/34.2μmol/L); glutamic-pyruvic transaminase (ALT) and/or Aspartate Aminotransferase (AST)≤3\*ULN (upper limit of normal).
* Normal electrocardiogram, echocardiography and myocardial enzyme spectrumCalibration of blood calcium concentration≤ULN.
* Men and women, Non-pregnant women who did not consider giving birth during the trial or five years after the end of the trial.
* The patient is able to swallow the capsule.
* Patients must provide written consent.

Exclusion Criteria:

* Severe allergies to the study drug or any of its excipients.
* The possibility of gene toxicity, mutagenesis and teratogenicity.
* Men and women who did not have sperm or egg cells stored in vitro before the trial and who planned to have children again within five years.
* Pregnant or lactating women.
* Perform autologous bone marrow transplantation 3 months before admission.
* Receive allogeneic bone marrow transplantation.
* Use HDAC inhibitors before.
* Two weeks prior to admission, received radiotherapy or bone marrow suppressive chemotherapy or biological treatment.
* Patients with history of other malignant tumors, except the tumor is in remission and has not been treated for at least 5 years.
* Patients with dysphagia or oral absorption disorder.
* The investigators determine the conditions not suitable for the study.

• BACKGROUNDHuang B, Lu J, Wang X, Xiao Y, Zhao Y, Huang H, Liu J, Chen M, Gu J, Yuan S, Zheng D, Li Y, Huang X, Li J. Prognostic value of lactate dehydrogenase in Chinese patients with newly diagnosed transplant eligible multiple myeloma. Leuk Lymphoma. 2017 Jul;58(7):1740-1742. doi: 10.1080/10428194.2016.1252975. Epub 2016 Nov 23. No abstract available. PMID 27881052
• BACKGROUNDLu J, Lu J, Chen W, Huo Y, Huang X, Hou J; Chinese Medical Doctor Association Hematology Branch. Clinical features and treatment outcome in newly diagnosed Chinese patients with multiple myeloma: results of a multicenter analysis. Blood Cancer J. 2014 Aug 15;4(8):e239. doi: 10.1038/bcj.2014.55. PMID 25127393
• BACKGROUNDRajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, Kumar S, Hillengass J, Kastritis E, Richardson P, Landgren O, Paiva B, Dispenzieri A, Weiss B, LeLeu X, Zweegman S, Lonial S, Rosinol L, Zamagni E, Jagannath S, Sezer O, Kristinsson SY, Caers J, Usmani SZ, Lahuerta JJ, Johnsen HE, Beksac M, Cavo M, Goldschmidt H, Terpos E, Kyle RA, Anderson KC, Durie BG, Miguel JF. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014 Nov;15(12):e538-48. doi: 10.1016/S1470-2045(14)70442-5. Epub 2014 Oct 26. PMID 25439696
• BACKGROUNDDurie BG, Salmon SE. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer. 1975 Sep;36(3):842-54. doi: 10.1002/1097-0142(197509)36:33.0.co;2-u. PMID 1182674
• BACKGROUNDPalumbo A, Avet-Loiseau H, Oliva S, Lokhorst HM, Goldschmidt H, Rosinol L, Richardson P, Caltagirone S, Lahuerta JJ, Facon T, Bringhen S, Gay F, Attal M, Passera R, Spencer A, Offidani M, Kumar S, Musto P, Lonial S, Petrucci MT, Orlowski RZ, Zamagni E, Morgan G, Dimopoulos MA, Durie BG, Anderson KC, Sonneveld P, San Miguel J, Cavo M, Rajkumar SV, Moreau P. Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group. J Clin Oncol. 2015 Sep 10;33(26):2863-9. doi: 10.1200/JCO.2015.61.2267. Epub 2015 Aug 3.